Dual specificity phosphatases in prostate cancer

Molecular and Cellular Endocrinology

Volumn 309, Issue 1-2, 2009, Pages 1-7

  Arnoldussen, Yke Jildouw ^a   Saatcioglu, Fahri ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

DUSPs; MAPKs; MKPs; Prostate cancer

Indexed keywords

CURCUMIN; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE 3; GINGEROL; METRIBOLONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN C FOS; PROTEIN C JUN; RAPAMYCIN; RESVERATROL; STRESS ACTIVATED PROTEIN KINASE;

CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CLINICAL TRIAL; ENZYME ACTIVITY; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

DUAL-SPECIFICITY PHOSPHATASES; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS;

EID: 67651171187     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.05.019     Document Type: Review

References (75)

1. Aguirre-Ghiso J.A., Estrada Y., Liu D., and Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res. 63 (2003) 1684-1695
2. Alonso A., Sasin J., Bottini N., Friedberg I., Friedberg I., Osterman A., Godzik A., Hunter T., Dixon J., and Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 117 (2004) 699-711
3. Altuwaijri S., Lin H.K., Chuang K.H., Lin W.J., Yeh S., Hanchett L.A., Rahman M.M., Kang H.Y., Tsai M.Y., Zhang Y., Yang L., and Chang C. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res. 63 (2003) 7106-7112
4. Arnoldussen Y.J., Lorenzo P.I., Pretorius M.E., Waehre H., Risberg B., Maelandsmo G.M., Danielsen H.E., and Saatcioglu F. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res. 68 (2008) 9255-9264
5. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., and Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63 (2003) 1981-1989
6. Barrett S.D., Bridges A.J., Dudley D.T., Saltiel A.R., Fergus J.H., Flamme C.M., Delaney A.M., Kaufman M., LePage S., Leopold W.R., Przybranowski S.A., Sebolt-Leopold J., Van Becelaere K., Doherty A.M., Kennedy R.M., Marston D., Howard Jr. W.A., Smith Y., Warmus J.S., and Tecle H. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg. Med. Chem. Lett. 18 (2008) 6501-6504
7. Boutros T., Chevet E., and Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 60 (2008) 261-310
8. Brondello J.M., Brunet A., Pouyssegur J., and McKenzie F.R. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 272 (1997) 1368-1376
9. Brondello J.M., Pouyssegur J., and McKenzie F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286 (1999) 2514-2517
10. Bu S., Blaukat A., Fu X., Heldin N.E., and Landstrom M. Mechanisms for 2-methoxyestradiol-induced apoptosis of prostate cancer cells. FEBS Lett. 531 (2002) 141-151
11. Carey A.M., Pramanik R., Nicholson L.J., Dew T.K., Martin F.L., Muir G.H., and Morris J.D. Ras-MEK-ERK signaling cascade regulates androgen receptor element-inducible gene transcription and DNA synthesis in prostate cancer cells. Int. J. Cancer 121 (2007) 520-527
12. Chan D.W., Liu V.W., Tsao G.S., Yao K.M., Furukawa T., Chan K.K., and Ngan H.Y. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29 (2008) 1742-1750
13. Chang L., and Karin M. Mammalian MAP kinase signalling cascades. Nature 410 (2001) 37-40
14. Chen L., He H.Y., Li H.M., Zheng J., Heng W.J., You J.F., and Fang W.G. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 215 (2004) 239-247
15. Chen S.Y., Cai C., Fisher C.J., Zheng Z., Omwancha J., Hsieh C.L., and Shemshedini L. c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene 25 (2006) 7212-7223
16. Chen Y., Sawyers C.L., and Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 8 (2008) 440-448
17. Chu Y., Solski P.A., Khosravi-Far R., Der C.J., and Kelly K. The mitogen-activated protein kinase phosphatases PAC1, MKP-1, and MKP-2 have unique substrate specificities and reduced activity in vivo toward the ERK2 sevenmaker mutation. J. Biol. Chem. 271 (1996) 6497-6501
18. Church D.R., Lee E., Thompson T.A., Basu H.S., Ripple M.O., Ariazi E.A., and Wilding G. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells. Prostate 63 (2005) 155-168
19. Denkert C., Schmitt W.D., Berger S., Reles A., Pest S., Siegert A., Lichtenegger W., Dietel M., and Hauptmann S. Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J. Cancer 102 (2002) 507-513
20. Dhanasekaran D.N., and Reddy E.P. JNK signaling in apoptosis. Oncogene 27 (2008) 6245-6251
21. Dhillon A.S., Hagan S., Rath O., and Kolch W. MAP kinase signalling pathways in cancer. Oncogene 26 (2007) 3279-3290
22. Engedal N., Korkmaz C.G., and Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 21 (2002) 1017-1027
23. Farooq A., Plotnikova O., Chaturvedi G., Yan S., Zeng L., Zhang Q., and Zhou M.M. Solution structure of the MAPK phosphatase PAC-1 catalytic domain. Insights into substrate-induced enzymatic activation of MKP. Structure 11 (2003) 155-164
24. Farooq A., and Zhou M.M. Structure and regulation of MAPK phosphatases. Cell Signal. 16 (2004) 769-779
25. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-45
26. Gioeli D., Mandell J.W., Petroni G.R., Frierson Jr. H.F., and Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59 (1999) 279-284
27. Greenberg N.M., DeMayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., and Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3439-3443
28. Grubb R., Deng J., Pinto P., Mohler J., Chinnaiyan A., Rubin M., Linehan W., Liotta L., Petricoin E., and Wulfkuhle J. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J. Proteome Res. (2009)
29. Heinlein C.A., and Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol. Endocrinol. 16 (2002) 2181-2187
30. Henkens R., Delvenne P., Arafa M., Moutschen M., Zeddou M., Tautz L., Boniver J., Mustelin T., and Rahmouni S. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 8 (2008) 147
31. Ikezoe T., Yang Y., Taguchi H., and Koeffler H.P. JNK interacting protein 1 (JIP-1) protects LNCaP prostate cancer cells from growth arrest and apoptosis mediated by 12-0-tetradecanoylphorbol-13-acetate (TPA). Br. J. Cancer 90 (2004) 2017-2024
32. Jeffrey K.L., Brummer T., Rolph M.S., Liu S.M., Callejas N.A., Grumont R.J., Gillieron C., Mackay F., Grey S., Camps M., Rommel C., Gerondakis S.D., and Mackay C.R. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat. Immunol. 7 (2006) 274-283
33. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
34. Jeong D.G., Cho Y.H., Yoon T.S., Kim J.H., Ryu S.E., and Kim S.J. Crystal structure of the catalytic domain of human DUSP5, a dual specificity MAP kinase protein phosphatase. Proteins 66 (2007) 253-258
35. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev. 27 (2008) 253-261
36. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., Sun Y., Ouyang X., Gerald W.L., Cordon-Cardo C., and Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118 (2008) 3051-3064
37. Krishnan A.V., Moreno J., Nonn L., Malloy P., Swami S., Peng L., Peehl D.M., and Feldman D. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J. Steroid Biochem. Mol. Biol. 103 (2007) 694-702
38. Kaarbo M., Klokk T.I., and Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29 (2007) 1227-1238
39. Leav I., Galluzzi C.M., Ziar J., Stork P.J., Ho S.M., and Loda M. Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest. 75 (1996) 361-370
40. Liao Q., Guo J., Kleeff J., Zimmermann A., Buchler M.W., Korc M., and Friess H. Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 124 (2003) 1830-1845
41. Loda M., Capodieci P., Mishra R., Yao H., Corless C., Grigioni W., Wang Y., Magi-Galluzzi C., and Stork P.J. Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 149 (1996) 1553-1564
42. Lorenzo P.I., Arnoldussen Y.J., and Saatcioglu F. Molecular mechanisms of apoptosis in prostate cancer. Crit. Rev. Oncog. 13 (2007) 1-38
43. Lorenzo P.I., and Saatcioglu F. Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. Neoplasia 10 (2008) 418-428
44. Magi-Galluzzi C., Mishra R., Fiorentino M., Montironi R., Yao H., Capodieci P., Wishnow K., Kaplan I., Stork P.J., and Loda M. Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 76 (1997) 37-51
45. Magi-Galluzzi C., Montironi R., Cangi M.G., Wishnow K., and Loda M. Mitogen-activated protein kinases and apoptosis in PIN. Virchows. Arch. 432 (1998) 407-413
46. Mandl M., Slack D.N., and Keyse S.M. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. Mol. Cell Biol. 25 (2005) 1830-1845
47. Maroni P.D., Koul S., Meacham R.B., and Koul H.K. Mitogen activated protein kinase signal transduction pathways in the prostate. Cell. Commun. Signal. 2 (2004) 5
48. Mojzis J., Varinska L., Mojzisova G., Kostova I., and Mirossay L. Antiangiogenic effects of flavonoids and chalcones. Pharmacol. Res. 57 (2008) 259-265
49. Navarro D., Luzardo O.P., Fernandez L., Chesa N., and Diaz-Chico B.N. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 81 (2002) 191-201
50. Nonn L., Duong D., and Peehl D.M. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 28 (2007) 1188-1196
51. Nonn L., Peng L., Feldman D., and Peehl D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res. 66 (2006) 4516-4524
52. Ouyang X., Jessen W.J., Al-Ahmadie H., Serio A.M., Lin Y., Shih W.J., Reuter V.E., Scardino P.T., Shen M.M., Aronow B.J., Vickers A.J., Gerald W.L., and Abate-Shen C. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res. 68 (2008) 2132-2144
53. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
54. Pang X., Yi T., Yi Z., Cho S.G., Qu W., Pinkaew D., Fujise K., and Liu M. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res. 69 (2009) 518-525
55. Papatsoris A.G., Karamouzis M.V., and Papavassiliou A.G. The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol. Cancer Ther. 6 (2007) 811-819
56. Patterson K.I., Brummer T., O'Brien P.M., and Daly R.J. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 418 (2009) 475-489
57. Peehl D.M., Shinghal R., Nonn L., Seto E., Krishnan A.V., Brooks J.D., and Feldman D. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 92 (2004) 131-141
58. Rauhala H.E., Porkka K.P., Tolonen T.T., Martikainen P.M., Tammela T.L., and Visakorpi T. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int. J. Cancer 117 (2005) 738-745
59. Ricote M., Garcia-Tunon I., Fraile B., Fernandez C., Aller P., Paniagua R., and Royuela M. P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells. Apoptosis 11 (2006) 1969-1975
60. Royuela M., Arenas M.I., Bethencourt F.R., Sanchez-Chapado M., Fraile B., and Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum. Pathol. 33 (2002) 299-306
61. Schubbert S., Shannon K., and Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7 (2007) 295-308
62. Schumacher M.A., Todd J.L., Rice A.E., Tanner K.G., and Denu J.M. Structural basis for the recognition of a bisphosphorylated MAP kinase peptide by human VHR protein Phosphatase. Biochemistry 41 (2002) 3009-3017
63. Srikanth S., Franklin C.C., Duke R.C., and Kraft R.S. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol. Cell Biochem. 199 (1999) 169-178
64. Stewart A.E., Dowd S., Keyse S.M., and McDonald N.Q. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat. Struct. Biol. 6 (1999) 174-181
65. Tao X., and Tong L. Crystal structure of the MAP kinase binding domain and the catalytic domain of human MKP5. Protein Sci. 16 (2007) 880-886
66. Theodosiou, A. and Ashworth, A. (2002) MAP kinase phosphatases. Genome Biol, 3, REVIEWS3009.
67. Tonks N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell Biol. 7 (2006) 833-846
68. Uzgare A.R., Kaplan P.J., and Greenberg N.M. Differential expression and/or activation of P38MAPK, ERK1/2, and JNK during the initiation and progression of prostate cancer. Prostate 55 (2003) 128-139
69. Vivanco I., Palaskas N., Tran C., Finn S.P., Getz G., Kennedy N.J., Jiao J., Rose J., Xie W., Loda M., Golub T., Mellinghoff I.K., Davis R.J., Wu H., and Sawyers C.L. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 11 (2007) 555-569
70. Wada T., and Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23 (2004) 2838-2849
71. Wang H.Y., Cheng Z., and Malbon C.C. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191 (2003) 229-237
72. Wang J., Zhou J.Y., and Wu G.S. ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells. Cancer Res. 67 (2007) 11933-11941
73. Wu G.S. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev. 26 (2007) 579-585
74. Yu W., Imoto I., Inoue J., Onda M., Emi M., and Inazawa J. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26 (2007) 1178-1187
75. Zheng X., Chang R.L., Cui X.X., Avila G.E., Hebbar V., Garzotto M., Shih W.J., Lin Y., Lu S.E., Rabson A.B., Kong A.N., and Conney A.H. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice. Clin Cancer Res. 12 (2006) 3444-3451